Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Invion ( (AU:IVX) ).
Invion Limited has announced a pro-rata non-renounceable offer of Loyalty Options to eligible shareholders as part of its capital management and clinical development strategy. The proceeds from this offer will support ongoing research and development, including a Phase I/II trial for anogenital cancer in collaboration with the Peter MacCallum Cancer Centre. This initiative is expected to raise up to $1 million initially, with potential for an additional $16 million if all options are exercised, bolstering Invion’s efforts to expand its clinical pipeline and enhance its market positioning.
More about Invion
Invion Limited is a company operating in the biotechnology industry, focusing on developing next-generation treatments using its Photosoft™ technology. The company is involved in clinical trials for non-melanoma skin cancer and anogenital cancer, aiming to advance therapeutic and diagnostic solutions, particularly in combination with immune checkpoint inhibitors for challenging cancers.
Average Trading Volume: 97,676
Technical Sentiment Signal: Sell
Current Market Cap: A$10.17M
For a thorough assessment of IVX stock, go to TipRanks’ Stock Analysis page.